Arcutis Biotherapeutics ARQT

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.22 (+1.52%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Arcutis Biotherapeutics (ARQT)
    Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $14.72

    • Market Cap

      $1.75 Billion

    • Price-Earnings Ratio

      -12.69

    • Total Outstanding Shares

      118.64 Million Shares

    • Total Employees

      342

    • Dividend

      No dividend

    • IPO Date

      January 31, 2020

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      3027 townsgate road, Westlake village, CA, 91361

    • Homepage

      https://www.arcutis.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow From Investing Activities, Continuing$28.82 Million
    Net Cash Flow From Investing Activities$28.82 Million
    Net Cash Flow From Operating Activities$-112.16 Million
    Net Cash Flow From Financing Activities, Continuing$66.20 Million
    Net Cash Flow$-17.14 Million
    Net Cash Flow From Financing Activities$66.20 Million

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Cost Of Revenue$19.13 Million
    Research and Development$76.42 Million
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Operating Income/Loss$-128.40 Million
    Income/Loss From Continuing Operations After Tax$-140.04 Million
    Income/Loss From Continuing Operations Before Tax$-128.40 Million

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Other Comprehensive Income/Loss Attributable To Parent$-11,000
    Comprehensive Income/Loss Attributable To Parent$-140.05 Million
    Comprehensive Income/Loss$-140.05 Million
    Other Comprehensive Income/Loss$-140.05 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Other Non-current Liabilities$3.13 Million
    Assets$348.89 Million
    Liabilities$191.35 Million
    Fixed Assets$1.04 Million
    Equity$157.54 Million
    Accounts Payable$14.22 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ARQT from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.